

# Contents

<b>Acknowledgments</b> .....	5
<b>Abbreviations</b> .....	6
<b>Preface</b> .....	8
<b>1. INTRODUCTION</b> .....	10
<b>1.1 Epidemiology</b> .....	10
<b>1.2 Disease pathogenesis</b> .....	10
<b>1.3 Risk factors</b> .....	12
Genetic factors .....	12
Environmental risk factors .....	12
<b>1.4 Clinical presentation</b> .....	12
Neurological symptoms .....	12
Cognitive symptoms .....	15
<b>1.5 Paraclinical measures</b> .....	16
Magnetic resonance imaging .....	16
Biochemical .....	18
Optical coherent tomography .....	18
<b>1.6 Diagnosis</b> .....	18
<b>1.7 Management</b> .....	19
<b>1.8 Prediction of disease activity</b> .....	20
<b>1.9 Disease monitoring</b> .....	21
<b>2. MAIN AIMS OF THE CURRENT WORK</b> .....	22
<b>3. METHODS</b> .....	24
<b>3.1 Brain MRI</b> .....	24
MRI acquisition .....	24
MRI analysis in BNAC .....	25
MRI analysis in Prague .....	25
<b>3.2 Clinical assessment</b> .....	25
Neuropsychological assessment .....	25
Neurological assessment .....	26

<b>4. SAMPLE</b> .....	27
4.1 SET study .....	27
4.2 Avonex-Steroid-Azathioprine (ASA) study .....	28
4.3 Grant Quantitative (GQ) study .....	29
4.4 The quantitative magnetic resonance imaging (QMRI) program ...	30
4.5 Healthy controls .....	32
<b>5. SUMMARY OF SELECTED STUDIES</b> .....	33
5.1 A novel semiautomated pipeline to measure brain atrophy .....	33
5.2 Evolution of brain volume loss rates in early stages of multiple sclerosis .....	35
5.3 Pathological cut-offs of brain volume loss .....	36
5.4 Interpretation of brain volume increase in multiple sclerosis .....	38
5.5 Occurrence of non-linear brain volume loss in patients with MS ..	39
5.6 MRI phenotypes according to dissociation between the brain atrophy and lesion burden using a new definition .....	43
5.7 The role of high-frequency MRI monitoring in the detection of brain atrophy .....	45
5.8 Early MRI and clinical predictors of disability progression over 6 years in patients after first clinical event suggestive of multiple sclerosis .....	46
5.9 Early MRI predictors of clinical progression after 48 months in CIS patients treated with intramuscular interferon beta-1a ...	48
5.10 Combining clinical and MRI markers enhances prediction of 12-year disability .....	49
5.11 Identification of MS patients at highest risk of cognitive impairment using integrated brain MRI assessment approach ...	52
5.12 Cognitive clinico-radiological paradox in early stages of multiple sclerosis .....	54
5.13 Pregnancy-induced brain MRI changes in women with multiple sclerosis .....	56
<b>6. SUMMARY AND FUTURE DIRECTIONS</b> .....	59
6.1 Time course and stability of brain atrophy .....	59
6.2 Relationship between brain atrophy and lesion burden accumulation .....	60
6.3 Prognostic role of MRI atrophy measures .....	61
6.4 Recommendations for use of brain atrophy measures in clinical practice .....	62
6.5 MRI phenotypes .....	63
6.6 Summary of the main findings .....	64
<b>References</b> .....	66